Dapagliflozin

Dapagliflozin (Farxiga, AstraZeneca) vs. placebo for improvements in symptoms and physical limitations in HF with preserved ejection fraction.

Healio and Cardiology Today have compiled a list of the most-read cardiology news of September 2021.

Dapagliflozin improved symptoms and physical limitations in patients with HF with preserved ejection fraction, according to results from the PRESERVED-HF trial.

Compared with placebo, dapagliflozin reduced risk for ventricular arrhythmias, cardiac arrest and sudden death, according to new data from the DAPA-HF trial.

Recent data showed that 8 or more hours of daily sedentary leisure time increased the risk for stroke in people aged younger than 60 years. It was the top story in cardiology last week.

In a simulation model, the addition of dapagliflozin to guideline-directed medical therapy in patients with HF with reduced ejection fraction improved long-term clinical outcomes while proving cost-effective at current U.S. prices.

An analysis of DAPA-CKD data showed dapagliflozin reduces the risk for kidney failure and mortality in patients with advanced chronic kidney disease, a subgroup that made up 14% of the study population included in the initial trial.

In 1989, the FDA’s approval of Epogen – epoetin alfa manufactured by Amgen Inc. – offered patients with kidney disease an opportunity to break away from blood transfusions, the washout after dialysis and improve their quality of life.

In April, the FDA approved use of dapagliflozin (Farxiga, AstraZeneca)to reduce the risk for kidney function decline, kidney failure, cardiovascular death and hospitalization for heart failure in adults with chronic kidney disease.

The SGLT2 inhibitor dapagliflozin is well-tolerated in adults hospitalized with COVID-19, regardless of diabetes status, according to new analyses from the DARE-19 trial.